Dr. Rosenberg on Complexity of Online Patient Information From NCI Cancer Center Websites

Video

In Partnership With:

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.

Researchers examined various NCI-designated websites to collect patient-specific information and enter it through readability software. Ten common readability tests were administered and it was determined that the majority of information was written at a high school senior/college freshman level. However, the United States Department of Human Health and Services requests that such information should be written at a sixth-grade level for the general population, Rosenberg says.

These findings demonstrate that online information provided to patients was not written at a level that patients could understand. There is a wide disconnect between what NCI-designated cancer centers are doing to provide information to patients versus what they should be doing, Rosenberg adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,